SavedAdd your journal

Journals / MN Kardiyoloji / 2012 / Cilt: 19 - Sayı: 4

Specific treatment of the pulmonary hypertension associated with left-sided heart failure and chronic obsructive pulmonary ddisease

Sol kalp yetersizliği veya kronik obstrüktif akciğer hastalığına bağlı gelişen pulmoner hipertansiyonda özgül tedavi

MEHMET HAKAN TAŞOLAR
Hasan PEKDEMİR
Pages
207–213
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review, specific treatment options of the pulmonary hypertension due to left-sided heart failure and chronic obstructive pulmonary disease were discussed.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Developments have rather been achieved in the treatment of pulmonary arterial hypertension along with the thorough understanding of the pathophysiology of it during the past decade.
📊
Key Findings & Data:Although many specific therapies have been developed in the treatment of pulmonary arterial hypertension with the clinical trials, the effects of these treatments on the secondary pulmonary hypertension is still unclear.
💡
Conclusion & Impact:In this review, specific treatment options of the pulmonary hypertension due to left-sided heart failure and chronic obstructive pulmonary disease were discussed.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Developments have rather been achieved in the treatment of pulmonary arterial hypertension along with the thorough understanding of the pathophysiology of it during the past decade. Although many specific therapies have been developed in the treatment of pulmonary arterial hypertension with the clinical trials, the effects of these treatments on the secondary pulmonary hypertension is still unclear. In this review, specific treatment options of the pulmonary hypertension due to left-sided heart failure and chronic obstructive pulmonary disease were discussed.

Özet

Son on yılda pulmoner hipertansiyon patofizyolojisinin iyice anlaşılması ile birlikte tedavide oldukça gelişmeler kaydedilmiştir. Klinik çalışmalar ile pulmoner arteryel hipertansiyon tedavisinde birçok özgül tedaviler geliştirilmiş olmasına rağmen bu tedavilerin sekonder pulmoner hipertansiyon üzerindeki etkileri hala net olarak bilinmemektedir. Bu derlemede sol kalp yetersizliği ve kronik obstrüktif akciğer hastalığına bağlı pulmoner hipertansiyonda özgül tedavi seçenekleri tartışılmıştır.

🔖

Cite This Article

TAŞOLAR, M. H., PEKDEMİR, H. (2012). Specific treatment of the pulmonary hypertension associated with left-sided heart failure and chronic obsructive pulmonary ddisease. MN Kardiyoloji, Cilt: 19 - Sayı: 4, 207–213. https://ajindex.com/articles/297402

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Hatano S, Strasser T. World Health Organization 1975. Primary pulmonary hypertension. Geneva: WHO; 1975
  2. D’Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991; 115:343-9
  3. Task Force for Diagnosis and Treatment of Pulmonary Hypertension of European Society of Cardiology (ESC); European Respiratory Society (ERS); International Society of Heart and Lung Transplantation (ISHLT), Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009;34:1219-63
  4. Tuder RM, Abman SH, Braun T, et al. Pulmonary circulation: development and pathology. J Am Coll Cardiol 2009;54:S3-9
  5. Moraes D, Colucci W, Givertz MM. Secondary pulmonary hypertension in chronic heart failure: the role of the endothelium in pathoPAHysiology and management. Circulation 2000;102:1718-23
  6. Cooper CJ, Jevnikar FW, Walsh T, Dickinson J, Mouhaffel A, Selwyn AP. The influence of basal nitric oxide activity on pulmonary vascular resistance in patients with congestive heart failure. Am J Cardiol 1998;82:609-14
  7. Lunn RJ.Inhaled nitric oxide therapy. Mayo Clin Proc 1995;70:247-55
  8. Lepore JJ, Dec GW, Zapol WM, Bloch KD, Semigran MJ. Combined administration of intravenous dipyridamole and inhaled nitric oxide to assess reversibility of pulmonary arterial hypertension in potential cardiac transplant recipients. J Heart Lung Transplant 2005;24:1950-6
  9. Semigran MJ, Cockrill BA, Kacmarek R, et al. Hemodynamic effects of inhaled nitric oxide in heart failure. J Am Coll Cardiol 1994;24:982-8
  10. Koelling T, Kirmse M, Di Salvo TG, Dec GW, Zapol WM, Semigran MJ. Inhaled nitric oxide improves exercise capacity in patients with severe heart failure and right ventricular dysfunction. Am J Cardiol 1998;81:1494-7
  11. Loh E, Stamler JS, Hare JM, Loscalzo J, Colucci WS. Cardiovascular effects of inhaled nitric oxide in patients with left ventricular dysfunction. Circulation 1994;90:2780-5
  12. Kieler-Jensen N, Ricksten SE, Stenqvist O, et al. Inhaled nitric oxide in the evaluation of heart transplant candidates with elevated pulmonary vascular resistance. J Heart Lung Transplant 1994;13:366-75
  13. Ohmae M. Endothelin-1 levels in chronic congestive heart failure. Wien Klin Wochenschr 2011;123(23- 24):714-7. doi: 10.1007/s00508-011-0097-6
  14. Mylona P, Cleland JG. Update of REACH-1 and MERIT-HF clinical trials in heart failur